MultiCare Deaconess Cancer and Blood Specialty Center - Valley — Spokane Valley, Washington

MultiCare Deaconess Cancer and Blood Specialty Center - Valley is a clinical research site located in Spokane Valley, Washington, United States 99216.

Crixeo Health Trust Score: 84/100 (GOOD). This profile has not yet been claimed by the site owner.

MultiCare Deaconess Cancer and Blood Specialty Center - Valley has participated in 77 clinical trials with 53 currently active.

Therapeutic areas: Choriocarcinoma, FIGO Stage I Gestational Trophoblastic Tumor, FIGO Stage II Gestational Trophoblastic Tumor.

Sponsors: GOG Foundation, National Cancer Institute (NCI), SWOG Cancer Research Network.

Sponsor Feasibility Report

Trust Score: 84/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for MultiCare Deaconess Cancer and Blood Specialty Center - Valley?

MultiCare Deaconess Cancer and Blood Specialty Center - Valley has a Crixeo Trust Score of 84/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has MultiCare Deaconess Cancer and Blood Specialty Center - Valley conducted?

MultiCare Deaconess Cancer and Blood Specialty Center - Valley has 77 clinical trials on record, with 53 currently active. Their work covers Choriocarcinoma, FIGO Stage I Gestational Trophoblastic Tumor, FIGO Stage II Gestational Trophoblastic Tumor.

Is MultiCare Deaconess Cancer and Blood Specialty Center - Valley accredited by Crixeo Health?

MultiCare Deaconess Cancer and Blood Specialty Center - Valley has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about MultiCare Deaconess Cancer and Blood Specialty Center - Valley?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.